I am new to the ins and outs of the litigation and to the FDA process of moving drugs to generic status. Can someone catch me up / summarize where things stand on modafinil?
It sounds like Teva/Celaphon still have a corner on the market as they are now acting as suppliers to other manufacturers, such as Par. Do we know what Par's costs are?
Then it seems that with the above announcement, Mylan will begin shipping it August 10th, but will they produce it themselves or will they also purchase from Teva/Celaphon?
Why isn't it possible to see the entire agreement? Shouldn't this be available to the public if the FDA is involved in signing off on it?
Finally, how do Barr, Ranbaxy Labs and Watson Pharmaceuticals fit in. They had also made an agreement with Cephalon to delay selling generic modafinil until April, 2012. Why can't they now begin production?

Reply With Quote





